Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield

From the US Army Austere and Wilderness Medicine Fellowship, Madigan Army Medical Center (I.S.W.), Joint Base Lewis-McChord, Washington
The journal of trauma and acute care surgery 12/2012; 73(6 Suppl 5):S490-5. DOI: 10.1097/TA.0b013e3182754674
Source: PubMed


Acute pain, resulting from trauma and other causes, is a common condition that imposes a need for prehospital analgesia on and off the battlefield. The narcotic most frequently used for prehospital analgesia on the battlefield during the past century has been morphine. Intramuscular morphine has a delayed onset of pain relief that is suboptimal and difficult to titrate. Although intravenously administered morphine can readily provide rapid and effective prehospital analgesia, oral transmucosal fentanyl citrate (OTFC) is a safe alternative that does not require intravenous access. This study evaluates the safety and efficacy of OTFC in the prehospital battlefield environment.
Data collected during combat deployments (Afghanistan and Iraq) from March 15, 2003, to March 31, 2010, were analyzed. Patients were US Army Special Operations Command casualties. Patients receiving OTFC for acute pain were evaluated. Pretreatment and posttreatment pain intensities were quantified by the verbal numeric rating scale (NRS) from 0 to 10. OTFC adverse effects and injuries treated were also evaluated.
A total of 286 patients were administered OTFC, of whom 197 had NRS pain evaluations conducted before and approximately 15 minutes to 30 minutes following treatment. The difference between NRS pain scores at 0 minutes (NRS, 8.0 [1.4]) and 15 minutes to 30 minutes (NRS, 3.2 [2.1]) was significant (p < 0.001). Only 18.3% (36 of 197) of patients were also administered other types of analgesics. Nausea was the most common adverse effect as reported by 12.7% (25 of 197) of patients. The only major adverse effect occurred in the patient who received the largest opioid dose, 3,200-µg OTFC and 20-mg morphine. This patient exhibited hypoventilation and saturation of less than 90% requiring low-dose naloxone.
OTFC is a rapid and noninvasive pain management strategy that provides safe and effective analgesia in the prehospital battlefield setting. OTFC has considerable implications for use in civilian prehospital and austere environments.
Therapeutic study, level IV.

23 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Owing to advanced protective technologies, many servicemembers are returning home with injuries that proved fatal in previous conflicts. However, such severe injuries provide numerous challenges for acute pain physicians. Advanced regional anesthetic techniques provide an essential multimodal tool that optimizes pain and minimizes opioid use. Utilization of such techniques in current conflicts has progressed from a rare occurrence owing to limited equipment and personnel to a widely use array of techniques utilized on the battlefield and continued throughout transport stateside. Such an evolution has enhanced the development of acute pain medicine services within the military that deliver such techniques along with noninterventional techniques. Further, such acute pain medicine services are well received in a combat theater and may serve as an optimal model in future conflicts. Preliminary experience within the last decade has described the interplay of such techniques with anticoagulation regimens in such trauma patients, incidence of infection, levels of serum local anesthetics in patients with multiple catheters, and the utility of such techniques in patients who may be at risk for compartment syndrome but must bear with a long transport chain back home. Looking forward, future training of personnel and tracking of outcomes are essential in optimizing the utility of such techniques in forward environments, but the collection of accurate outcome data will also determine if prolonged benefits can be realized in addition to the obvious benefit downrange.
    Techniques in Regional Anesthesia [amp ] Pain Management 10/2012; 16(4):184–189. DOI:10.1053/j.trap.2013.08.004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper is the thirty-fifth consecutive installment of the annual review of research concerning the endogenous opioid system. It summarizes papers published during 2012 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior (Section 2), and the roles of these opioid peptides and receptors in pain and analgesia (Section 3); stress and social status (Section 4); tolerance and dependence (Section 5); learning and memory (Section 6); eating and drinking (Section 7); alcohol and drugs of abuse (Section 8); sexual activity and hormones, pregnancy, development and endocrinology (Section 9); mental illness and mood (Section 10); seizures and neurologic disorders (Section 11); electrical-related activity and neurophysiology (Section 12); general activity and locomotion (Section 13); gastrointestinal, renal and hepatic functions (Section 14); cardiovascular responses (Section 15); respiration and thermoregulation (Section 16); and immunological responses (Section 17).
    Peptides 10/2013; 50. DOI:10.1016/j.peptides.2013.10.001 · 2.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To be honest, I thought this would be a lost cause. Even after skipping a New Drugs and Devices essay in 2012, I figured that I would have to search long and hard to find 10 new things that emergency practitioners needed to know about. Although there were no true blockbuster medications for emergency physicians, I nonetheless found 10 medicines that we probably should know, along with a new device that may change the way we work up patients with palpitations, and a clever new delivery system for subcutaneous epinephrine.
    The western journal of emergency medicine 11/2013; 14(6):619-628. DOI:10.5811/westjem.2013.2.16210
Show more